http://www.elsevier.com/gej-ng/10/42/35/60/75/28/abstract.html
Please note! As of 2002 online access to
full-text articles is available to all readers whose library
|
Vaccine, Vol. 20 (31-32) (2002) pp. 3632-3634
© 2002 Elsevier Science Ltd. All rights reserved.
PII: S0264-410X(02)00377-8
a Institut National de Santé Publiqùe du Québec,
2400 rue d'Estimauville, Beauport, Qué., Canada G1E 7G9
b Unité de recherche en santé publique, Centre
hospitalier universitaire de Québec, Institut National de santé publique du
Québec, Université Laval, Québec, Qué., Canada
c Ministère de la Santé et des Services sociaux, du
Québec, Québec, Qué., Canada G1T 2K4
Received 17 March 2002; received in revised form 15 July 2002; accepted 26 July 2002
A small proportion of healthy children fail to develop antibodies against hepatitis B after three doses of vaccine. Few data are available regarding the optimal re-immunization strategy. We measured the immune response 1 month after a single supplementary dose of recombinant hepatitis B vaccines in 18 young preadolescents who were non- or hyporesponsive after a regular primary course of three doses of recombinant hepatitis B vaccines. Among them, 100% seroconverted and 89% reached the seroprotective titer of 10milli-International Units (mIU)/ml. Most healthy children, particularly if they are hyporesponders, will have reached the seroprotective level after one dose and will not need further injections.
Keywords: Hepatitis B vaccine; Revaccination; Preadolescents
*Corresponding author. Tel.: +418-666-7000x234; fax: +418-666-2776.
Full text supplied by [ScienceDirect]
© Copyright 2002, Elsevier Science, All rights reserved.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.